SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is experiencing extreme volatility following news that its flagship NHS-Galleri cancer screening trial missed its primary endpoint, despite beating Q4 revenue and EPS estimates. While some in the community see the massive price drop as an overreaction to misunderstood trial results, others are concerned about the long-term viability and potential for further decline.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending following recent positive comments from PepsiCo regarding its distribution partnership and Alani Nu integration, alongside a J.P. Morgan price target raise. The community is actively discussing the stock's growth potential and speculating on a possible PepsiCo acquisition, amidst ongoing concerns about stock price stability and management's communication leading into upcoming financial events.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following news of a proposed $100 million public stock offering and a $100 million royalty funding agreement, sparking intense community debate. While many shareholders express frustration over perceived dilution and management's strategy, supporters argue these moves are crucial to secure long-term financing and maintain independence for advancing its clinical pipeline toward potential commercialization.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending amid community discussions regarding its latest Q4 earnings, which showed strong IBSRELA revenue growth offset by increased strategic investments, and recent news of a patent extension until 2042 for its key products. Additionally, investors are actively weighing the initiation of a new Phase 3 trial for IBSRELA and ongoing rumors of a potential acquisition by Zydus Lifesciences, with many expressing frustration over the stock's perceived undervaluation despite these developments.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending following investor concerns about its path to profitability and weak guidance shared during its recent earnings call, sparking community debate over the 'buy now, pay never' business model amidst significant stock price drops.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending after its Q4 earnings surpassed analyst expectations with strong revenue, EPS, and record free cash flow. However, investor sentiment is mixed, as many express frustration over the muted stock reaction, citing concerns about lower production guidance and higher projected costs for 2026.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending as its transformative all-stock acquisition of Valaris creates an offshore drilling powerhouse, driving community excitement for substantial synergies, a bolstered backlog, and potential for a significant re-rating ahead of its anticipated earnings report.

AIOS Foundation

AIOS is trending after its recent ticker change from NISN, sparking community debate over its potential as a low-float artificial intelligence play versus concerns about potential scams and future offerings.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is trending due to circulating rumors of a strategic OpenAI partnership for monetizing ChatGPT, fueling a robust rebound and intense debate among investors. This comes as the company navigates a competitive ad-tech landscape, with many bulls citing strong underlying earnings as a reason to buy the dip.

EPAM Systems, Inc. engages in the provision of digital engineering, cloud, and artificial intelligence-enabled transformation services. The firm combines software engineering with customer experience design, business consulting, strategy, and technology innovation services in areas such as cloud platforms, cybersecurity, and artificial intelligence. It operates through the North America and Europe geographical segments. The company was founded by Leonid Lozner and Arkadiy Dobkin in 1993 and is headquartered in Newtown, PA.

EPAM Systems Inc

EPAM Systems is trending following its latest earnings report, which, despite beating Q4 expectations, included conservative FY25 guidance leading to a sharp stock decline. The market is now divided, with some investors seeing a strong "buy the dip" opportunity in the oversold IT services firm, while others remain cautious about the broader sector's demand recovery and AI-driven shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2030 Earnings Forecast for SGMO Issued By HC Wainwright

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a report issued on Tuesday...

Sangamo Therapeutics (NASDAQ:SGMO) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen downgraded shares of Sangamo Therapeutics to a "strong sell" rating in a report on Saturday...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Hold" from Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has been given a consensus recommendation of "Hold" by the seven ratings firms that are presently covering the firm, MarketBeat Ratings...

Sangamo Therapeutics (NASDAQ:SGMO) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Sangamo Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Saturday...

Research Analysts Offer Predictions for SGMO FY2025 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright decreased their FY2025 earnings per share estimates for Sangamo Therapeutics in a report released on Monday, November 10th. HC...

Q4 Earnings Forecast for SGMO Issued By HC Wainwright

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright issued their Q4 2025 earnings estimates for shares of Sangamo Therapeutics in a note issued to investors on Monday, November...

Sangamo Therapeutics (NASDAQ:SGMO) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus...

Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -266.67% and -98.84%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

What Makes Sangamo (SGMO) a New Buy Stock

Sangamo (SGMO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

SGMO
Sangamo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMO News

SGMOSangamo Therapeutics Inc